Cargando…

Erratum: Krayem, M., et al. Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance Short Title: Sensitivity Prediction to MAPK Inhibitors in Melanoma. Cancers 2020, 12, 512

Detalles Bibliográficos
Autores principales:	Krayem, Mohammad, Aftimos, Philippe, Najem, Ahmad, van den Hooven, Tim, van den Berg, Adriënne, Hovestad-Bijl, Liesbeth, de Wijn, Rik, Hilhorst, Riet, Ruijtenbeek, Rob, Sabbah, Malak, Kerger, Joseph, Awada, Ahmad, Journe, Fabrice, Ghanem, Ghanem E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Erratum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7602461/ https://www.ncbi.nlm.nih.gov/pubmed/33066704 http://dx.doi.org/10.3390/cancers12102981

Ejemplares similares

Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance Short Title: Sensitivity Prediction to MAPK Inhibitors in Melanoma
por: Krayem, Mohamad, et al.
Publicado: (2020)

The Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in Melanoma
por: Krayem, Mohammad, et al.
Publicado: (2019)

RTK Inhibitors in Melanoma: From Bench to Bedside
por: Sabbah, Malak, et al.
Publicado: (2021)

Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma
por: Krayem, Mohammad, et al.
Publicado: (2018)

Understanding Molecular Mechanisms of Phenotype Switching and Crosstalk with TME to Reveal New Vulnerabilities of Melanoma
por: Najem, Ahmad, et al.
Publicado: (2022)

Targeting Prohibitins to Inhibit Melanoma Growth and Overcome Resistance to Targeted Therapies
por: Najem, Ahmad, et al.
Publicado: (2023)

Toad Venom Antiproliferative Activities on Metastatic Melanoma: Bio-Guided Fractionation and Screening of the Compounds of Two Different Venoms
por: Soumoy, Laura, et al.
Publicado: (2020)

Metabolic Reprogramming in Metastatic Melanoma with Acquired Resistance to Targeted Therapies: Integrative Metabolomic and Proteomic Analysis
por: Soumoy, Laura, et al.
Publicado: (2020)

The benefit of co-targeting PARP-1 and c-Met on the efficacy of radiotherapy in wild type BRAF melanoma
por: Sabbah, Malak, et al.
Publicado: (2023)

Tyrosine-Dependent Phenotype Switching Occurs Early in Many Primary Melanoma Cultures Limiting Their Translational Value
por: Najem, Ahmad, et al.
Publicado: (2021)

PRIMA-1 and PRIMA-1(Met) (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies
por: Perdrix, Anne, et al.
Publicado: (2017)

FGF2 Induces Resistance to Nilotinib through MAPK Pathway Activation in KIT Mutated Melanoma
por: Tétu, Pauline, et al.
Publicado: (2020)

Role of Macrophage Migration Inhibitory Factor (MIF) in Melanoma
por: Soumoy, Laura, et al.
Publicado: (2019)

Regorafenib Induces Senescence and Epithelial-Mesenchymal Transition in Colorectal Cancer to Promote Drug Resistance
por: Kehagias, Pashalina, et al.
Publicado: (2022)

The MAPK pathway as an apoptosis enhancer in melanoma
por: Haydn, Johannes M., et al.
Publicado: (2014)

Suppression of heparan sulfation re-sensitizes YAP1-driven melanoma to MAPK pathway inhibitors
por: Dieter, Sebastian M., et al.
Publicado: (2022)

T-type calcium channel inhibition restores sensitivity to MAPK inhibitors in de-differentiated and adaptive melanoma cells
por: Granados, Karol, et al.
Publicado: (2020)

Data-Derived Modeling Characterizes Plasticity of MAPK Signaling in Melanoma
por: Bernardo-Faura, Marti, et al.
Publicado: (2014)

SPRED1 deletion confers resistance to MAPK inhibition in melanoma
por: Ablain, Julien, et al.
Publicado: (2020)

Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state
por: Verfaillie, Annelien, et al.
Publicado: (2015)

Restoring p53 Function in Head and Neck Squamous Cell Carcinoma to Improve Treatments
por: de Bakker, Tycho, et al.
Publicado: (2022)

Melanoma cells resistant towards MAPK inhibitors exhibit reduced TAp73 expression mediating enhanced sensitivity to platinum-based drugs
por: Makino, Elena, et al.
Publicado: (2018)

Targeting of the MAPK and AKT pathways in conjunctival melanoma shows potential synergy
por: Cao, Jinfeng, et al.
Publicado: (2016)

Counteracting oxidative phosphorylation-mediated resistance of melanomas to MAPK pathway inhibition
por: McQuade, Jennifer L, et al.
Publicado: (2015)

Gut Microbiota and Therapy in Metastatic Melanoma: Focus on MAPK Pathway Inhibition
por: Guardamagna, Mora, et al.
Publicado: (2022)

Dasatinib Resensitizes MAPK Inhibitor Efficacy in Standard-of-Care Relapsed Melanomas
por: Rebecca, Vito W., et al.
Publicado: (2023)

Cytokine Landscape in Central Nervous System Metastases
por: Marin, Julie, et al.
Publicado: (2022)

In vitro long-term treatment with MAPK inhibitors induces melanoma cells with resistance plasticity to inhibitors while retaining sensitivity to CD8 T cells
por: Rowdo, Florencia Paula Madorsky, et al.
Publicado: (2017)

Hypoxia Promotes Uveal Melanoma Invasion through Enhanced Notch and MAPK Activation
por: Asnaghi, Laura, et al.
Publicado: (2014)

ZEB1‐mediated melanoma cell plasticity enhances resistance to MAPK inhibitors
por: Richard, Geoffrey, et al.
Publicado: (2016)

β-Lapachone suppresses the lung metastasis of melanoma via the MAPK signaling pathway
por: Kee, Ji-Ye, et al.
Publicado: (2017)

Intermittent Versus Continuous Dosing of MAPK Inhibitors in the Treatment of BRAF-Mutated Melanoma
por: Reger de Moura, Coralie, et al.
Publicado: (2019)

Shikonin inhibits proliferation of melanoma cells by MAPK pathway-mediated induction of apoptosis
por: Lee, Jae Han, et al.
Publicado: (2021)

Blocking Genomic Instability Prevents Acquired Resistance to MAPK Inhibitor Therapy in Melanoma
por: Dharanipragada, Prashanthi, et al.
Publicado: (2023)

Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity
por: Lee, Shannon, et al.
Publicado: (2020)

The BRAF–MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells
por: Sumimoto, Hidetoshi, et al.
Publicado: (2006)

Computational Modeling of PI3K/AKT and MAPK Signaling Pathways in Melanoma Cancer
por: Pappalardo, Francesco, et al.
Publicado: (2016)

Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma
por: Deken, Marcel A., et al.
Publicado: (2016)

TERT promoter mutations in melanoma render TERT expression dependent on MAPK pathway activation
por: Vallarelli, Andrelou F., et al.
Publicado: (2016)

PAK Signaling Drives Acquired Drug Resistance to MAPK Inhibitors in BRAF-mutant Melanomas
por: Lu, Hezhe, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_9af8uhkq0n0qrj5j69n3f4jlrf